ARYX THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -.--% |
|
-.--% | -.--% |
| Sales 2008 | 19.72 1.64K | Sales 2009 | - | Capitalization | 88.66M 7.39B |
|---|---|---|---|---|---|
| Net income 2008 | -31M -2.58B | Net income 2009 | -33M -2.75B | EV / Sales 2008 | 40,19,605 x |
| Net cash position 2008 | 29.9 2.49K | Net Debt 2009 | 2.37 197.69 | EV / Sales 2009 | - |
| P/E ratio 2008 |
-1.76
x | P/E ratio 2009 |
-2.66
x | Employees | 56 |
| Yield 2008 * |
-
| Yield 2009 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More press releases
1 year
0.00
0.00
3 years
0.000.04
5 years
0.000.05
10 years
0.000.05
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 33 | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ARYX Stock
